Efficacy of Non-invasive Neuromodulation Treatments for COVID-19 Sequelae
ConditionCovid-19 Recurrent
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorClinica Gema Leon
About this trial
The goal of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19. It will also estimate the impact of non-invasive neuromodulation treatment on the functionality and quality of life of patients with COVID-19 sequelae.The main question it aim to answer is:
\- Is non-invasive neuromodulation effective as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19.
Researchers will compare non-invasive neuromodulation to a placebo (treatment with the machine turned off).
Participants will:
* Be evaluated before starting treatment. * Be evaluated 3 weeks after. * Be evaluated at 5 weeks, or 15 sessions or completion of treatment. * Be evaluated 6 weeks after finishing the treatment or 11 weeks after starting treatment.
Eligibility criteria
Qualifiers
Patients between the ages of 18 and 60.
Patients with a positive diagnosis of COVID-19.
Patients with post-COVID-19 sequelae with musculoskeletal, respiratory or neurological symptoms due to taste or smell lasting at least 30 days, with no history of respiratory and/or neurological and/or musculoskeletal diseases.
Patients who signed the informed consent.
Disqualifiers
Patients aged before 18 years and after 60 years.
Healthy people with no history of neurological, neurological and/or respiratory and/or musculoskeletal diseases
Patients with secondary diseases that could directly affect the systems to be evaluated who were not diagnosed positive for COVID-19.
Trial design
Treatments tested in this trial
- Non invasive neuromodulation therapy
- Manual therapy
- Placebo with non invasive neuromodulation
Treatment groups
104 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov